Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TTI-101 |
Synonyms | |
Therapy Description |
TTI-101 (C188-9) is a small molecule that binds to STAT3 and inhibits signaling, potentially resulting in tumor cell death (PMID: 27027445, PMID: 32475130). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TTI-101 | TTI101|TTI 101|C188-9 | STAT3 Inhibitor 26 | TTI-101 (C188-9) is a small molecule that binds to STAT3 and inhibits signaling, potentially resulting in tumor cell death (PMID: 27027445, PMID: 32475130). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05845307 | Phase I | TTI-101 | Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck | Not yet recruiting | USA | 0 |
NCT03195699 | Phase I | TTI-101 | Phase I Study of Oral STAT3 Inhibitor, C188-9, in Patients With Advanced Cancers | Completed | USA | 0 |
NCT06141031 | Phase Ib/II | TTI-101 | Phase 1/2 Trial of Radiotherapy in Combination With TTI-101 in Patients With Borderline Resectable Pancreatic Cancer | Suspended | USA | 0 |
NCT05440708 | Phase Ib/II | Atezolizumab + Bevacizumab + TTI-101 TTI-101 Pembrolizumab + TTI-101 | A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | Recruiting | USA | 0 |